Topic: Diabetic Macular Edema
Kodiak Sciences sold a capped 4.5% royalty on its eye disease drug that could rival Eylea in exchange for $225 million in development funding.
A collaboration between Unity Biotech and Ascentage Pharma has yielded a development candidate to treat age-related diseases of the eye.
Kodiak Sciences has filed to raise up to $100 million in its IPO to support the development of its anti-VEGF drug for eye diseases.
Allegro is busy working to see its eye disease candidate risuteganib into the final stages of testing, and will now have a new chief to help it through phase 3.
Roche's antibody RG7716 in diabetic macular edema could be a threat to current blockbuster VEGF drugs used for the disease.
The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea.
KalVista has been looking for a big pharma partner for its plasma kallikrein inhibitors, and just had its wish fulfilled by Merck & Co.